Campus Access Only
All rights reserved. This publication is intended for use solely by faculty, students, and staff of University of the Pacific. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, now known or later developed, including but not limited to photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author or the publisher.
Date of Award
2013
Document Type
Dissertation - Pacific Access Restricted
Degree Name
Doctor of Philosophy (Ph.D.)
Department
Pharmaceutical and Chemical Sciences
First Advisor
Wade Russu
First Committee Member
William Chan
Second Committee Member
Andreas Franz
Third Committee Member
Jerry Tsai
Fourth Committee Member
Geoff Lin-Cereghino
Abstract
NF-κB is a transcription factor protein complex that plays an important role in some cancers and inflammatory responses. It can enhance the proliferation rate, reduce apoptosis, as well as create more blood flow to ensure the survival of cancer. Thus blocking the NF-κB pathway has potential therapeutic benefit. We designed a series of compounds based on quinazoline scaffold pharmacophore model which may have high binding affinity with p50 subunit of NF-κB. The compound series with phenyl substitution at position 2 of quinazoline proved to be more effective at inhibiting NF-κB function both theoretically and experimentally. These compounds also reduce the proliferation of numerous tumor cell lines and the mean GI50 for representative compound 2a is 2.88μM on NCI 60 cell lines. Compound 2a can induce significant apoptosis at the concentration of 1μM. The exploration of the mechanism of action of these compounds found that 2a does not inhibit kinases upstream of NF-κB and does not inhibit p65 translocation from the cytosol to the nucleus as 2b does. However 2a inhibits NF-κB dependent Luciferase expression as well as NF-κB target genes better than 2b. This may suggest that 2a inhibits the NF-κB pathway by directly blocking gene transcription, while 2b acts at cytoplasmic stage.
Pages
135
ISBN
9781303319990
Recommended Citation
Xu, Lu. (2013). New quinazoline analogues as NF-κB activation inhibitors. University of the Pacific, Dissertation - Pacific Access Restricted. https://scholarlycommons.pacific.edu/uop_etds/152
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
To access this thesis/dissertation you must have a valid pacific.edu email address and log-in to Scholarly Commons.
Find in PacificSearch Find in ProQuestIf you are the author and would like to grant permission to make your work openly accessible, please email
Rights Statement
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
